CLINICAL AND PROGNOSTIC-SIGNIFICANCE OF SERUM MAGNESIUM CONCENTRATION IN PATIENTS WITH SEVERE CHRONIC CONGESTIVE-HEART-FAILURE - THE PROMISE STUDY

被引:63
作者
EICHHORN, EJ
TANDON, PK
DIBIANCO, R
TIMMIS, GC
FENSTER, PE
SHANNON, J
PACKER, M
机构
[1] ASTRA PHARMACEUT PROD INC, WESTBOROUGH, MA USA
[2] WASHINGTON ADVENTIST HOSP, TAKOMA PK, MD USA
[3] STERLING WINTHROP RES INST, MALVERN, PA USA
[4] UNIV ARIZONA, MED CTR, CARDIOL SECT, TUCSON, AZ 85721 USA
[5] COLUMBIA UNIV COLL PHYS & SURG, DIV CIRCULATORY PHYSIOL, NEW YORK, NY 10032 USA
[6] WILLIAM BEAUMONT HOSP, ROYAL OAK, MI 48072 USA
关键词
D O I
10.1016/0735-1097(93)90095-I
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. The aim of this study was to determine the prognostic significance of alterations in serum magnesium in patients with moderate to severe congestive heart failure. Background. Reductions in serum magnesium have been postulated to play a role in promoting arrhythmias and to have an adverse impact on survival in congestive heart failure, although support for this postulate is lacking. Methods. Serum magnesium levels were measured in 1,068 patients enrolled in a survival study of class III or IV heart failure at the time of double-blind randomization to milrinone, a phosphodiesterase inhibitor, or placebo. All patients received conventional therapy with digoxin, diuretic drugs and a converting enzyme inhibitor throughout the trial. The median follow-up period was 6.1 months (range 1 day to 20 months). Results. Patients with high serum magnesium (defined as greater-than-or-equal-to 1.9 mEq/liter, n = 242) were less likely to survive than were patients with a normal magnesium level (n = 627) (p < 0.05, risk ratio = 1.41). Patients with a low magnesium level (defined as less-than-or-equal-to 1.5 mEq/liter, n = 199) had no difference in survival compared with the group with a normal magnesium level (p = NS, risk ratio = 0.89). At baseline, the patients in the high magnesium group were older and had more severe functional and renal impairment. An analysis after adjustment for these variables demonstrated no difference in survival comparing the low, normal and high magnesium groups. Although the three groups had no difference in frequency of ventricular tachycardia, length of longest run or frequency of ventricular premature beats on baseline Holter monitoring, the group with hypomagnesemia had more frequent ventricular couplets. Conclusions. Serum magnesium does not appear to be an independent risk factor for either sudden death or death due to all causes in patients with moderate to severe heart failure. Hypomagnesemia is associated with an increase in the frequency of certain forms of ventricular ectopic activity, but this is not associated with an increase in clinical events. The higher mortality rate among the patients with hypermagnesemia is attributable to older age, more advanced heart failure and renal insufficiency.
引用
收藏
页码:634 / 640
页数:7
相关论文
共 44 条
  • [1] MAGNESIUM IN THE PREVENTION OF LETHAL ARRHYTHMIAS IN ACUTE MYOCARDIAL-INFARCTION
    ABRAHAM, AS
    ROSENMANN, D
    KRAMER, M
    BALKIN, J
    ZION, MM
    FARBSTIEN, H
    EYLATH, U
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (04) : 753 - 755
  • [2] MODULATION OF CARDIAC ION CHANNELS BY MAGNESIUM
    AGUS, ZS
    MORAD, M
    [J]. ANNUAL REVIEW OF PHYSIOLOGY, 1991, 53 : 299 - 307
  • [3] CYTOSOLIC MAGNESIUM MODULATES CALCIUM-CHANNEL ACTIVITY IN MAMMALIAN VENTRICULAR CELLS
    AGUS, ZS
    KELEPOURIS, E
    DUKES, I
    MORAD, M
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 256 (02): : C452 - C455
  • [4] ALBITZ R, 1990, EUR BIOPHYS J, V19, P19, DOI 10.1007/BF00223569
  • [5] MAGNESIUM SUPPRESSION OF EARLY AFTERDEPOLARIZATIONS AND VENTRICULAR TACHYARRHYTHMIAS INDUCED BY CESIUM IN DOGS
    BAILIE, DS
    INOUE, H
    KASEDA, S
    BENDAVID, J
    ZIPES, DP
    [J]. CIRCULATION, 1988, 77 (06) : 1395 - 1402
  • [6] CHADDA K, 1984, CIRCULATION, V70, P444
  • [7] PLASMA NOREPINEPHRINE AS A GUIDE TO PROGNOSIS IN PATIENTS WITH CHRONIC CONGESTIVE HEART-FAILURE
    COHN, JN
    LEVINE, TB
    OLIVARI, MT
    GARBERG, V
    LURA, D
    FRANCIS, GS
    SIMON, AB
    RECTOR, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (13) : 819 - 823
  • [8] MORTALITY AND MORBIDITY IN PATIENTS RECEIVING ENCAINIDE, FLECAINIDE, OR PLACEBO - THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL
    ECHT, DS
    LIEBSON, PR
    MITCHELL, LB
    PETERS, RW
    OBIASMANNO, D
    BARKER, AH
    ARENSBERG, D
    BAKER, A
    FRIEDMAN, L
    GREENE, HL
    HUTHER, ML
    RICHARDSON, DW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (12) : 781 - 788
  • [9] HYPOMAGNESEMIA IN THE PATIENT RECEIVING DIGITALIS
    FLINK, EB
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (04) : 625 - 626
  • [10] SURVIVAL IN MEN WITH SEVERE CHRONIC LEFT-VENTRICULAR FAILURE DUE TO EITHER CORONARY HEART-DISEASE OR IDIOPATHIC DILATED CARDIOMYOPATHY
    FRANCIOSA, JA
    WILEN, M
    ZIESCHE, S
    COHN, JN
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1983, 51 (05) : 831 - 836